Video Case
Video Case
In 2019, Amgen acquired the Copenhagen-based biopharmaceutical company Nuevolution, now known as Amgen Research Copenhagen (ARC).
Now, 4 years later Alex Gouliaev, Vice President of Research looks back and shares what life science companies can expect when they invest in Denmark and what, in his perspective makes Denmark stand out.
When
Amgen is a leading global pharmaceutical company committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering human therapeutics.
Denmark is a preferred location for clinical trials and research, if you are interested to learn more, click the link to read our article "Amgen: Denmark - a preferred location for clinical trials and research".
Please contact our dedicated experts here:
Title: Investment Manager - Life Science & Digital Health
Area: Silicon Valley
Email: [email protected]
Phone: +1 (650) 272-9510
Title: Special Advisor - Life Sciences
Area: Aarhus
Email: [email protected]
Phone: +45 2856 8540
Title: Team Leader - Life Sciences & Food
Area: Copenhagen
Email: [email protected]
Phone: +45 3392 1350
